Literature DB >> 6160353

Clinical electrophysiological properties of N-allyl-clonidine (ST 567) in man.

W Kasper, T Meinertz, N Treese, F Kersting, T Pop, E Jähnchen.   

Abstract

The electrophysiological properties of N-allyl-clonidine (ST 567) were studied in 18 patients. Four of these patients were pretreated with intravenous propranolol, 0.2 mg/kg, and atropine, 0.04 mg/kg, to induce autonomic blockade. ST 567 produces a sustained bradycardiac effect at a dose of 40 mg, i.v., in patients without (group I) and with (group II) autonomic blockade. The mean increase in Group I was 23% and in group II, 42%. The sinus node recovery time increased in both groups, from 1,151 +/- 73 to 1,310 +/- 81 msec in group I, and from 995 +/- 145 to 1,599 +/- 248 msec (means +/- SEM) in group II. The corrected sinus node recovery time was unaffected by ST 567 in Group I and increased from 165 +/- 50 to 427 +/- 117 msec in group II. The sinoatrial conduction time was unaffected by ST 567 in group I. The effective refractory period of the right atrium, the atrioventricular node and the right ventricle, as well as the functional refractory period of the atrioventricular node, were unaffected by ST 567 in patients without autonomic blockade. Intra-atrial, atrioventricular, and intraventricular conduction were also not altered by this drug. Thus, the electrophysiological profile of ST 567 differs from other bradycardia-inducing agents such as beta-blockers or calcium antagonists.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6160353     DOI: 10.1097/00005344-198101000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Proof of the linearity of the pharmacokinetics of alinidine in man.

Authors:  D Arndts; H Warnkross; K L Rominger; H Justus
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats.

Authors:  W D Bechtel; I Richter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

3.  Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome.

Authors:  B Stanek; W Reiterer; P Placheta; G Raberger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs.

Authors:  D Arndts; G Leb; H J Förster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

5.  Comparative effects of alinidine and propranolol in ischaemic heart disease.

Authors:  J Schurmans; J Piessens; H Kesteloot; H De Geest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.